

Trevor R Norman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8571460/publications.pdf>

Version: 2024-02-01

202
papers

5,066
citations

87888

38
h-index

123424

61
g-index

205
all docs

205
docs citations

205
times ranked

4444
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnostic agreement and concordance between consultation-liaison psychiatry and non-psychiatric (medical and surgical) doctors: changes within junior doctorâ€™s terms. <i>Australasian Psychiatry</i> , 2022, 30, 60-63.	0.7	2
2	Desvenlafaxine in the treatment of major depression: an updated overview. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1087-1097.	1.8	6
3	Agomelatine: Profile and applications to depression. , 2021, , 301-308.		0
4	Agomelatine for depression: expanding the horizons?. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 647-656.	1.8	40
5	Problematic medical marijuana, but not all cannabinoids?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2018, 52, 95-95.	2.3	0
6	5-HT2A Agonists: A Novel Therapy for Functional Neurological Disorders?. <i>International Journal of Neuropsychopharmacology</i> , 2017, 20, 422-427.	2.1	12
7	Pharmacotherapy for Mood and Anxiety Disorders. <i>Mental Health and Illness Worldwide</i> , 2017, , 427-453.	0.1	1
8	Agomelatine, Melatonin and Depression. , 2016, , 229-247.		2
9	Pharmacotherapy for Mood and Anxiety Disorders. <i>Mental Health and Illness Worldwide</i> , 2016, , 1-27.	0.1	0
10	Impairments of Spatial Working Memory and Attention Following Acute Psychosocial Stress. <i>Stress and Health</i> , 2015, 31, 115-123.	2.6	80
11	One-Year Treatment Continuation in Patients Switched to Paliperidone Palmitate. <i>Journal of Clinical Psychiatry</i> , 2014, 75, 1267-1269.	2.2	7
12	Agomelatine, melatonin and depressive disorder. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 407-410.	4.1	3
13	The effect of agomelatine on 5HT2C receptors in humans: a clinically relevant mechanism?. <i>Psychopharmacology</i> , 2012, 221, 177-178.	3.1	4
14	Agomelatine suppresses locomotor hyperactivity in olfactory bulbectomised rats: A comparison to melatonin and to the 5-HT2c antagonist, S32006. <i>European Journal of Pharmacology</i> , 2012, 674, 27-32.	3.5	24
15	Duloxetine in the acute and continuation treatment of major depressive disorder. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 1525-1539.	2.8	0
16	The Decline and Fall of the Psychopharmacology Empire?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2011, 45, 1005-1005.	2.3	0
17	Contemporary Therapies for Depression in Older People. <i>Journal of Pharmacy Practice and Research</i> , 2010, 40, 58-64.	0.8	3
18	Dopamine D1 receptor binding in the anterior cingulate cortex of patients with obsessiveâ€“compulsive disorder. <i>Psychiatry Research - Neuroimaging</i> , 2010, 183, 85-88.	1.8	31

#	ARTICLE	IF	CITATIONS
19	Continuation treatment of major depressive disorder: is there a case for duloxetine?. Drug Design, Development and Therapy, 2010, 4, 19.	4.3	13
20	Dysfunctional Circadian Rhythms and Mood Disorders: Opportunities for Novel Therapeutic Approaches. Modern Problems of Pharmacopsychiatry, 2010, , 32-52.	2.5	4
21	Duloxetine in the treatment of generalized anxiety disorder. Neuropsychiatric Disease and Treatment, 2009, 4, 1169.	2.2	11
22	The Impact of a Changed Environment on Arousal Levels of Patients in a Secure Extended Rehabilitation Facility. Australasian Psychiatry, 2009, 17, 207-211.	0.7	16
23	A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia. Journal of Clinical and Experimental Neuropsychology, 2009, 31, 848-859.	1.3	156
24	Dopamine D1 receptor binding in the striatum of patients with obsessive-compulsive disorder. Journal of Affective Disorders, 2009, 114, 321-326.	4.1	68
25	Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with bupirone, a partial 5-HT _{1A} receptor agonist. Human Psychopharmacology, 2009, 24, 437-446.	1.5	32
26	Stability of cognitive impairment in chronic schizophrenia over brief and intermediate retest intervals. Human Psychopharmacology, 2009, 24, 113-121.	1.5	40
27	Melatonin: hormone of the night. Acta Neuropsychiatrica, 2009, 21, 263-265.	2.1	5
28	Abnormal dose-response melatonin suppression by light in bipolar type I patients compared with healthy adult subjects. Acta Neuropsychiatrica, 2009, 21, 246-255.	2.1	29
29	The neurobiology of benzodiazepine receptors in panic disorder and post-traumatic stress disorder. Stress and Health, 2008, 24, 13-21.	2.6	6
30	How does your garden grow therapeutic principles from herbal remedies?. Stress and Health, 2008, 24, 1-2.	2.6	0
31	An investigation of the effect of immediate and extended release venlafaxine on nocturnal melatonin and cortisol release in healthy adult volunteers. Human Psychopharmacology, 2008, 23, 129-137.	1.5	7
32	Quetiapine augmentation in depressed patients with partial response to antidepressants. Human Psychopharmacology, 2008, 23, 653-660.	1.5	19
33	Spatial working memory and problem solving in schizophrenia: The effect of symptom stabilization with atypical antipsychotic medication. Psychiatry Research, 2008, 160, 316-326.	3.3	34
34	Ethnic differences in psychotropic drug response and pharmacokinetics. , 2008, , 38-61.		6
35	Combination Antidepressants are not yet Proven Therapy in the Treatment of Depression. Australasian Psychiatry, 2007, 15, 248-249.	0.7	4
36	Emerging treatments for major depression. Expert Review of Neurotherapeutics, 2007, 7, 203-213.	2.8	17

#	ARTICLE	IF	CITATIONS
37	Behavioural studies of spatial working memory dysfunction in schizophrenia: A quantitative literature review. <i>Psychiatry Research</i> , 2007, 150, 111-121.	3.3	142
38	An open-label study of quetiapine in anorexia nervosa. <i>Human Psychopharmacology</i> , 2007, 22, 223-230.	1.5	29
39	Neuropsychological study of underweight and "weight-recovered" anorexia nervosa compared with bulimia nervosa and normal controls. <i>International Journal of Eating Disorders</i> , 2007, 40, 613-621.	4.0	75
40	Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. <i>Acta Psychiatrica Scandinavica</i> , 2007, 116, 41-49.	4.5	317
41	A comparative study of sertraline dosages, plasma concentrations, efficacy and adverse reactions in Chinese versus Caucasian patients. <i>International Clinical Psychopharmacology</i> , 2006, 21, 87-92.	1.7	24
42	The heritability of melatonin secretion and sensitivity to bright nocturnal light in twins. <i>Psychoneuroendocrinology</i> , 2006, 31, 867-875.	2.7	68
43	Human Embryonic Stem Cells: A Resource for In Vitro Neuroscience Research?. <i>Neuropsychopharmacology</i> , 2006, 31, 2571-2572.	5.4	0
44	Prospects for the Treatment of Depression. <i>Australian and New Zealand Journal of Psychiatry</i> , 2006, 40, 394-401.	2.3	11
45	Brain serotonin depletion by lesions of the median raphe nucleus enhances the psychotomimetic action of phencyclidine, but not dizocilpine (MK-801), in rats. <i>Brain Research</i> , 2005, 1049, 217-226.	2.2	19
46	Serotonergic and Dopaminergic Systems in Anorexia Nervosa: A Role for Atypical Antipsychotics?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2005, 39, 146-153.	2.3	40
47	Effect of Sodium Valproate on Nocturnal Melatonin Sensitivity to Light in Healthy Volunteers. <i>Neuropsychopharmacology</i> , 2005, 30, 1400-1404.	5.4	82
48	Low doses of lithium carbonate reduce melatonin light sensitivity in healthy volunteers. <i>International Journal of Neuropsychopharmacology</i> , 2005, 8, 255-259.	2.1	61
49	Attenuation of benzodiazepine withdrawal anxiety in the rat by serotonin antagonists. <i>Behavioural Brain Research</i> , 2005, 161, 286-290.	2.2	11
50	Serotonergic and dopaminergic systems in anorexia nervosa: a role for atypical antipsychotics?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2005, 39, 146-153.	2.3	0
51	Melatonin sensitivity to light in monozygotic twins discordant for bipolar I disorder. <i>Australian and New Zealand Journal of Psychiatry</i> , 2005, 39, 947-947.	2.3	13
52	Mechanism of Action of Mirtazapine: Dual Action or Dual Effect?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2004, 38, 267-269.	2.3	0
53	The Emerging Role of Pharmacogenetics: Implications for Clinical Psychiatry. <i>Australian and New Zealand Journal of Psychiatry</i> , 2004, 38, 483-489.	2.3	8
54	Selective Effects of Acute Serotonin and Catecholamine Depletion on Memory in Healthy Women. <i>Journal of Psychopharmacology</i> , 2004, 18, 32-40.	4.0	92

#	ARTICLE	IF	CITATIONS
55	Mechanism of action of mirtazapine: dual action or dual effect?. Australian and New Zealand Journal of Psychiatry, 2004, 38, 267-269.	2.3	1
56	The emerging role of pharmacogenetics: implications for clinical psychiatry. Australian and New Zealand Journal of Psychiatry, 2004, 38, 483-489.	2.3	42
57	Blunted growth hormone response to clonidine in post-traumatic stress disorder. Psychoneuroendocrinology, 2004, 29, 269-278.	2.7	16
58	Fifth World Congress on Stress, London, 18-19 June 2004. Stress and Health, 2004, 20, 173-174.	2.6	0
59	The treatment of depression with different formulations of venlafaxine: a comparative analysis. Human Psychopharmacology, 2004, 19, 9-16.	1.5	45
60	New Formulations of Existing Antidepressants. CNS Drugs, 2004, 18, 505-520.	5.9	26
61	An investigation of the effect of tacrine and physostigmine on spatial working memory deficits in the olfactory bulbectomised rat. Behavioural Brain Research, 2004, 153, 481-486.	2.2	16
62	Prolactin response to d-fenfluramine in combat-related post-traumatic stress disorder. International Journal of Neuropsychopharmacology, 2004, 7, 291-298.	2.1	11
63	Blunted prolactin response to d-fenfluramine in post-stroke major depression. Journal of Affective Disorders, 2003, 76, 273-278.	4.1	12
64	Comparative cognitive and psychomotor effects of single doses of Valeriana officinalis and triazolam in healthy volunteers. Human Psychopharmacology, 2003, 18, 619-625.	1.5	36
65	Olanzapine in Anorexia Nervosa. Australian and New Zealand Journal of Psychiatry, 2003, 37, 494-494.	2.3	9
66	Olanzapine excretion in human breast milk: estimation of infant exposure. International Journal of Neuropsychopharmacology, 2002, 5, 243-7.	2.1	51
67	Brain monoamines and early visual information-processing speed. International Journal of Neuropsychopharmacology, 2002, 5, 295-300.	2.1	4
68	Effects of serotonin and catecholamine depletion on interleukin-6 activation and mood in human volunteers. Human Psychopharmacology, 2002, 17, 293-297.	1.5	20
69	Guest Editorial: International Society for the Investigation of Stress (ISIS). Stress and Health, 2002, 18, 59-60.	2.6	0
70	The effect of single oral doses of zopiclone on nocturnal melatonin secretion in healthy male volunteers. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2001, 25, 825-833.	4.8	8
71	Third-Generation Antidepressants. CNS Drugs, 2001, 15, 941-954.	5.9	57
72	Sertraline Analysis in the Plasma of Breast-Fed Infants. Australian and New Zealand Journal of Psychiatry, 2001, 35, 545-546.	2.3	14

#	ARTICLE	IF	CITATIONS
73	In vitro metabolism of mirtazapine enantiomers by human cytochrome P450 enzymes. Human Psychopharmacology, 2001, 16, 541-544.	1.5	44
74	Mechanisms underlying the speed of onset of antidepressant response. , 2001, , 47-61.		0
75	Sertraline in paired blood plasma and breast-milk samples from nursing mothers. Human Psychopharmacology, 2000, 15, 161-264.	1.5	27
76	Stress induced animal models of depression. Stress and Health, 2000, 16, 195-197.	0.5	2
77	Pindolol Augmentation of Antidepressants: A Review and Rationale. Australian and New Zealand Journal of Psychiatry, 2000, 34, 71-79.	2.3	27
78	Chiral determination of mirtazapine in human blood plasma by high-performance liquid chromatography. Biomedical Applications, 2000, 748, 439-443.	1.7	44
79	The effect of gender on the melatonin suppression by light: a dose response relationship. Journal of Neural Transmission, 2000, 107, 271-279.	2.8	32
80	Acute increases in night-time plasma melatonin levels following a period of meditation. Biological Psychology, 2000, 53, 69-78.	2.2	116
81	Antidepressants and Breast-Feeding. Paediatric Drugs, 2000, 2, 183-192.	3.1	22
82	An open label trial of venlafaxine in war veterans with chronic post traumatic stress disorder. Australian and New Zealand Journal of Psychiatry, 2000, 34, A31-A31.	2.3	3
83	Nefazodone in the Breast Milk of Nursing Mothers: A Report of Two Patients. Journal of Clinical Psychopharmacology, 2000, 20, 717-718.	1.4	10
84	Presence of olanzapine in breast milk. Australian and New Zealand Journal of Psychiatry, 2000, 34, A16-A16.	2.3	1
85	A positron emission tomography study of benzodiazepine receptors in post-traumatic stress disorder. Australian and New Zealand Journal of Psychiatry, 2000, 34, A21-A21.	2.3	0
86	Determination of nefazodone and its pharmacologically active metabolites in human blood plasma and breast milk by high-performance liquid chromatography. Biomedical Applications, 1999, 730, 249-255.	1.7	22
87	The Evaluation of Depression in Inpatients with HIV Disease. Australian and New Zealand Journal of Psychiatry, 1999, 33, 344-352.	2.3	36
88	Onset of the Effects of the 5-HT _{1A} Antagonist, WAY-100635, Alone, and in Combination With Paroxetine, on Olfactory Bulbectomy and 8-OH-DPAT-Induced Changes in the Rat. Pharmacology Biochemistry and Behavior, 1999, 63, 333-338.	2.9	51
89	Effect of the menstrual cycle stage on the melatonin suppression by dim white light. Psychoneuroendocrinology, 1999, 24, 193-200.	2.7	10
90	Melatonin Sensitivity to Dim White Light in Affective Disorders. Neuropsychopharmacology, 1999, 21, 408-413.	5.4	106

#	ARTICLE	IF	CITATIONS
91	Melatonin sensitivity to dim white light in different seasons. <i>Human Psychopharmacology</i> , 1999, 14, 53-58.	1.5	7
92	Discontinuation Syndromes with Selective Serotonin Reuptake Inhibitors. <i>CNS Drugs</i> , 1999, 12, 171-177.	5.9	19
93	The Test Re-Test Reliability of the Melatonin Suppression by White Light. <i>Biological Rhythm Research</i> , 1999, 30, 467-475.	0.9	1
94	Treatment of Anxiety During Pregnancy. <i>Drug Safety</i> , 1999, 20, 171-186.	3.2	16
95	The effect of age and pre-light melatonin concentration on the melatonin sensitivity to dim light. <i>International Clinical Psychopharmacology</i> , 1999, 14, 189-192.	1.7	6
96	The effect of age and pre-light melatonin concentration on the melatonin sensitivity to dim light. <i>International Clinical Psychopharmacology</i> , 1999, 14, 189-192.	1.7	11
97	Modulation of plasma melatonin concentrations by changes in posture. <i>Journal of Pineal Research</i> , 1998, 24, 219-223.	7.4	29
98	Combining pindolol and paroxetine in an animal model of chronic antidepressant action—can early onset of action be detected?. <i>European Journal of Pharmacology</i> , 1998, 352, 23-28.	3.5	57
99	Neurochemical effects of the enantiomers of mirtazapine in normal rats. <i>European Journal of Pharmacology</i> , 1998, 356, 121-126.	3.5	23
100	Negative symptoms, depression and parkinsonian symptoms in chronic, hospitalised schizophrenic patients. <i>Journal of Affective Disorders</i> , 1998, 48, 163-169.	4.1	22
101	Plasma and human milk concentrations of moclobemide in nursing mothers. <i>Human Psychopharmacology</i> , 1998, 13, 579-582.	1.5	8
102	The effect of venlafaxine treatment on the behavioural and neurochemical changes in the olfactory bulbectomised rat. <i>Psychopharmacology</i> , 1998, 136, 394-401.	3.1	30
103	Platelet paroxetine binding in post-traumatic stress disorder. <i>Psychiatry Research</i> , 1998, 77, 1-7.	3.3	13
104	Evidence for 5-HT _{1A} receptor control of pineal melatonin concentrations in the rat. <i>European Neuropsychopharmacology</i> , 1998, 8, 183-186.	0.7	10
105	Subsensitive melatonin suppression by dim white light: possible biological marker of panic disorder. <i>International Journal of Neuropsychopharmacology</i> , 1998, 1, 115-120.	2.1	6
106	Aggressive behaviour and platelet 3H-paroxetine binding in schizophrenia. <i>Schizophrenia Research</i> , 1997, 23, 61-67.	2.0	15
107	5. Benzodiazepines in anxiety disorders: managing therapeutics and dependence. <i>Medical Journal of Australia</i> , 1997, 167, 490-495.	1.7	11
108	3. Assessment of anxiety and depression in primary care. <i>Medical Journal of Australia</i> , 1997, 167, 328-333.	1.7	19

#	ARTICLE	IF	CITATIONS
109	The effect of atenolol, a β_1 -adrenergic antagonist, on nocturnal plasma melatonin secretion: Evidence for a dose-response relationship in humans. <i>Journal of Pineal Research</i> , 1997, 23, 131-135.	7.4	24
110	The effect of dim light on suppression of nocturnal melatonin in healthy women and men. <i>Journal of Neural Transmission</i> , 1997, 104, 643-648.	2.8	27
111	ANTIDEPRESSANTS: CLINICAL ASPECTS. <i>Stress and Health</i> , 1997, 13, 167-172.	0.5	5
112	Successful treatment of serotonin syndrome with chlorpromazine. <i>Medical Journal of Australia</i> , 1996, 165, 345-346.	1.7	13
113	Overnight human plasma melatonin, Cortisol, prolactin, TSH, under conditions of normal sleep, sleep deprivation, and sleep recovery. <i>Journal of Pineal Research</i> , 1996, 20, 7-14.	7.4	96
114	Nocturnal plasma melatonin concentrations in healthy volunteers: Effect of single doses of d-fenfluramine, paroxetine, and ipsapirone. <i>Journal of Pineal Research</i> , 1996, 21, 55-58.	7.4	11
115	Platelet [3H]-paroxetine binding in obsessive-compulsive disorder. <i>Human Psychopharmacology</i> , 1995, 10, 141-146.	1.5	2
116	A Risk-Benefit Assessment of Moclobemide in the Treatment of Depressive Disorders. <i>Drug Safety</i> , 1995, 12, 46-54.	3.2	13
117	Platelet [3H]paroxetine binding in panic disorder. <i>Journal of Affective Disorders</i> , 1995, 33, 117-122.	4.1	11
118	Who bears the costs of antidepressants in Australia?. <i>Medical Journal of Australia</i> , 1995, 162, 162-162.	1.7	3
119	Suicide, violent behaviour and fluoxetine. <i>Medical Journal of Australia</i> , 1994, 161, 404-405.	1.7	3
120	Serotonergic function in panic disorder: Endocrine responses to d-Fenfluramine. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1994, 18, 329-337.	4.8	16
121	Differential Diagnosis and Drug Treatment of Panic Disorder, Anxiety and Depression. <i>CNS Drugs</i> , 1994, 1, 119-131.	5.9	8
122	Fast-Acting Antidepressants. <i>CNS Drugs</i> , 1994, 2, 120-131.	5.9	19
123	Plasma and breast milk concentrations of dothiepin and nortriaden in lactating women. <i>Human Psychopharmacology</i> , 1993, 8, 29-33.	1.5	19
124	Long-term drug treatment of panic disorder. <i>Journal of Psychiatric Research</i> , 1993, 27, 111-125.	3.1	19
125	Long-term management of depressive disorders. <i>Current Therapeutic Research</i> , 1993, 54, 832-837.	1.2	1
126	Alterations to Plasma Melatonin and Cortisol After Evening Alprazolam Administration in Humans. <i>Chronobiology International</i> , 1993, 10, 205-213.	2.0	63

#	ARTICLE	IF	CITATIONS
127	Pharmacokinetic aspects of antidepressant treatment in the elderly. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1993, 17, 329-344.	4.8	9
128	Prolactin response to dl-fenfluramine in panic disorder. Psychoneuroendocrinology, 1993, 18, 337-342.	2.7	24
129	A Multicentre Double Blind Trial of Fluoxetine versus Amitriptyline in the Treatment of Depressive Illness. Australian and New Zealand Journal of Psychiatry, 1993, 27, 49-55.	2.3	24
130	Fluoxetine " Delayed half-life and an Adverse Event. Medical Journal of Australia, 1993, 158, 722-723.	1.7	1
131	New Pharmacological Approaches to the Management of Depression: From Theory to Clinical Practice. Australian and New Zealand Journal of Psychiatry, 1992, 26, 73-81.	2.3	15
132	Buspirone and Fluoxetine in the Treatment of OCD. Australian and New Zealand Journal of Psychiatry, 1992, 26, 684-686.	2.3	2
133	Melatonin, cortisol and prolactin response to acute nocturnal light exposure in healthy volunteers. Psychoneuroendocrinology, 1992, 17, 243-248.	2.7	26
134	Stress and isatin: Effects on the serotonergic system. Stress and Health, 1992, 8, 141-145.	0.5	2
135	Fenfluramine Augmentation of Clomipramine Treatment of Obsessive Compulsive Disorder. Australian and New Zealand Journal of Psychiatry, 1991, 25, 412-414.	2.3	14
136	Pharmacokinetic and Pharmacodynamic Effects of a Single Nocturnal Dose of Alprazolam. International Clinical Psychopharmacology, 1990, 5, 111-118.	1.7	4
137	Pharmacotherapy of Panic Disorder. International Review of Psychiatry, 1990, 2, 399-409.	2.8	7
138	A Portable Light Source for Bright Light Treatment. Sleep, 1990, 13, 272-275.	1.1	3
139	Platelet MAO and 5-HT uptake in agoraphobics. British Journal of Psychiatry, 1990, 156, 592-593.	2.8	0
140	High-affinity platelet [3H]LSD binding is decreased in panic disorder. Journal of Affective Disorders, 1990, 19, 119-123.	4.1	10
141	Breastfeeding and the use of psychotropic medication: a review. Journal of Affective Disorders, 1990, 19, 197-206.	4.1	65
142	Treatment of Seasonal Affective Disorder with Light: Preliminary Australian Experience. Australian and New Zealand Journal of Psychiatry, 1989, 23, 369-372.	2.3	2
143	The effect of stress on melatonin and serotonin in rat brain. Stress and Health, 1989, 5, 5-8.	0.5	8
144	Human Melatonin Suppression by Light is Intensity Dependent. Journal of Pineal Research, 1989, 6, 149-156.	7.4	389

#	ARTICLE	IF	CITATIONS
145	Platelet serotonin uptake in panic disorder patients: A replication study. <i>Psychiatry Research</i> , 1989, 30, 63-68.	3.3	12
146	Quantal melatonin suppression by exposure to low intensity light in man. <i>Life Sciences</i> , 1989, 45, 327-332.	4.3	69
147	Platelet serotonin uptake and 3H-imipramine binding in panic disorder. <i>Journal of Affective Disorders</i> , 1989, 17, 77-81.	4.1	18
148	Platelet serotonin response to treatment in geriatric depression. <i>Biological Psychiatry</i> , 1989, 26, 434-436.	1.3	0
149	Human melatonin response to light at different times of the night. <i>Psychoneuroendocrinology</i> , 1989, 14, 187-193.	2.7	45
150	Treatment of Seasonal Affective Disorder with Light: Preliminary Australian Experience. <i>Australian and New Zealand Journal of Psychiatry</i> , 1989, 23, 369-372.	2.3	88
151	A Short Term Open Clinical Trial of Clobazam in the Treatment of Patients with Panic Attacks. <i>International Clinical Psychopharmacology</i> , 1989, 4, 285-294.	1.7	8
152	Serotonin in Panic Disorder. <i>International Clinical Psychopharmacology</i> , 1989, 4, 1-6.	1.7	71
153	Treatment of Seasonal Affective Disorder with Light: Preliminary Australian Experience. <i>Australian and New Zealand Journal of Psychiatry</i> , 1989, 23, 369-372.	2.3	17
154	Antidepressant Drug Measurement: Review of Methods for Clinical Application. , 1989, , 605-610.		0
155	Suppression of plasma melatonin by a single dose of the benzodiazepine alprazolam in humans. <i>Biological Psychiatry</i> , 1988, 24, 108-112.	1.3	52
156	A kinetic analysis of platelet monoamine oxidase activity in patients with panic attacks. <i>Journal of Affective Disorders</i> , 1988, 15, 127-130.	4.1	6
157	Platelet Serotonin Uptake in Panic Disorder: Comparison with Normal Controls and the Effect of Treatment. <i>Australian and New Zealand Journal of Psychiatry</i> , 1988, 22, 390-395.	2.3	10
158	A Case of Moclobemide Overdose. <i>International Clinical Psychopharmacology</i> , 1988, 3, 325-326.	1.7	10
159	Urinary Tribulin Output in Patients with Panic Attacks. <i>British Journal of Psychiatry</i> , 1988, 152, 295-296.	2.8	1
160	Low platelet monoamine oxidase and sensation seeking in males: an established relationship?. <i>Acta Psychiatrica Scandinavica</i> , 1987, 75, 86-90.	4.5	37
161	Plasma Prolactin and Fluphenazine Concentrations in Patients receiving Fluphenazine Decanoate: Stability over Injection Intervals. <i>International Clinical Psychopharmacology</i> , 1987, 2, 299-305.	1.7	4
162	Platelet 3H-rauwolscine binding in patients with panic attacks. <i>Psychiatry Research</i> , 1987, 22, 43-48.	3.3	14

#	ARTICLE	IF	CITATIONS
163	Platelet monoamine oxidase: Low activity in cigarette smokers. <i>Psychiatry Research</i> , 1987, 20, 199-205.	3.3	69
164	The pineal hormone melatonin in panic disorder. <i>Journal of Affective Disorders</i> , 1987, 12, 203-206.	4.1	18
165	Plasma immunoreactive β^2 -endorphin in dexamethasone suppressors and non-suppressors of cortisol. <i>Journal of Affective Disorders</i> , 1987, 12, 233-239.	4.1	8
166	Platelet monoamine uptake in depression ? primary or secondary phenomenon?. <i>Human Psychopharmacology</i> , 1987, 2, 47-47.	1.5	0
167	Melatonin Rhythm in Human Plasma Saliva. <i>Journal of Pineal Research</i> , 1987, 4, 177-183.	7.4	70
168	PLATELET MONOAMINE OXIDASE ACTIVITY IN PATIENTS WITH HUNTINGTON'S DISEASE. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1987, 14, 547-550.	1.9	7
169	Platelet serotonin uptake in panic disorder. <i>Journal of Affective Disorders</i> , 1986, 11, 69-72.	4.1	41
170	Melatonin in panic disorder. <i>Biological Psychiatry</i> , 1986, 21, 1438-1439.	1.3	6
171	Pharmacological Treatment of Panic Disorder. <i>International Clinical Psychopharmacology</i> , 1986, 1, 3-16.	1.7	27
172	Plasma fluphenazine concentrations in outpatients receiving fluphenazine decanoate (Modecate). <i>Human Psychopharmacology</i> , 1986, 1, 89-92.	1.5	1
173	Determination of tiapride in plasma by high-performance liquid chromatography. <i>Biomedical Applications</i> , 1986, 375, 197-201.	1.7	13
174	Plasma Melatonin Concentrations in Depression. <i>Australian and New Zealand Journal of Psychiatry</i> , 1986, 20, 381-383.	2.3	42
175	Anxiety and the Benzodiazepine Receptor. <i>Progress in Brain Research</i> , 1986, 65, 73-90.	1.4	8
176	Antidepressant therapy: benefits and risks in perspective. <i>Acta Psychiatrica Scandinavica</i> , 1985, 72, 43-47.	4.5	10
177	Analysis of tricyclic antidepressant drugs in plasma and serum by chromatographic techniques. <i>Biomedical Applications</i> , 1985, 340, 173-197.	1.7	34
178	The biological basis of anxiety. <i>Journal of Affective Disorders</i> , 1985, 9, 271-284.	4.1	38
179	A controlled study of a specific MAO a reversible inhibitor (R011-1163) and amitriptyline in depressive illness. <i>Journal of Affective Disorders</i> , 1985, 8, 29-35.	4.1	45
180	Plasma concentrations of benzodiazepines â€” A review of clinical findings and implications. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1984, 8, 115-126.	4.8	7

#	ARTICLE	IF	CITATIONS
181	Measurement of moclobamide, a new monoamine oxidase inhibitor, by gas chromatography with nitrogen-selective detection. Biomedical Applications, 1983, 278, 429-433.	1.7	18
182	The pharmacokinetics of mianserin in elderly depressed patients. Psychiatry Research, 1983, 8, 281-287.	3.3	12
183	Zimelidine: A placebo-controlled trial in depression. Psychiatry Research, 1983, 8, 95-103.	3.3	7
184	Maprotiline in affective illness. Journal of Affective Disorders, 1983, 5, 147-154.	4.1	5
185	Liver Impairment Associated with Nomifensine. Australian and New Zealand Journal of Psychiatry, 1983, 17, 288-289.	2.3	3
186	Psychosis after withdrawal of steroid therapy. Medical Journal of Australia, 1983, 2, 350-351.	1.7	11
187	Clinical evaluation of the cardiac effects of new psychotropic drugs. , 1983, , 83-98.		0
188	Monitoring and Interpretation of Antidepressant Plasma Concentrations. Australian and New Zealand Journal of Psychiatry, 1982, 16, 74-78.	2.3	0
189	Platelet monoamine oxidase activity and cigarette smoking. Journal of Affective Disorders, 1982, 4, 73-77.	4.1	59
190	A pharmacokinetic study of mianserin. European Journal of Clinical Pharmacology, 1982, 21, 517-520.	1.9	18
191	Metabolism and pharmacokinetics of dothiepin.. British Journal of Clinical Pharmacology, 1981, 12, 405-409.	2.4	22
192	Pharmacokinetics of N-desmethyldiazepam after a single oral dose of clorazepate: The effect of smoking. European Journal of Clinical Pharmacology, 1981, 21, 229-233.	1.9	24
193	Simultaneous measurement of dothiepin and its major metabolites in plasma and whole blood by gas chromatography-mass fragmentography. Biomedical Applications, 1981, 222, 399-408.	1.7	14
194	Doxepin Plasma Levels and Anxiolytic Response. International Pharmacopsychiatry, 1980, 15, 247-252.	0.4	4
195	Plasma Nomifensine Concentration. International Pharmacopsychiatry, 1980, 15, 325-333.	0.4	7
196	Viloxazine plasma concentrations and clinical response. Journal of Affective Disorders, 1980, 2, 157-164.	4.1	10
197	Psychotherapeutic Drugs. Drugs, 1980, 20, 485-493.	10.9	13
198	PHARMACOKINETICS AND PLASMA LEVELS OF ANTIDEPRESSANTS IN THE ELDERLY. Medical Journal of Australia, 1979, 1, 273-274.	1.7	15

#	ARTICLE	IF	CITATIONS
199	Cigarette smoking and plasma nortriptyline levels. Clinical Pharmacology and Therapeutics, 1977, 21, 453-456.	4.7	33
200	A CONTROLLED COMPARATIVE TRIAL OF CLORAZEPATE (TRANXENE) AND DIAZEPAM (VALIUM) FOR ANXIETY. Medical Journal of Australia, 1977, 2, 525-528.	1.7	9
201	Determination of therapeutic levels of butriptyline in plasma by gas-liquid chromatography. Journal of Chromatography A, 1977, 134, 524-528.	3.7	12
202	A NEW ANTIDEPRESSANT BUTRIPTYLINE: PLASMA LEVELS AND CLINICAL RESPONSE. Medical Journal of Australia, 1977, 2, 604-606.	1.7	8